Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 9Adenocarcinoma of Lung 4Adenocarcinoma, Bronchiolo-Alveolar 2Solitary Pulmonary Nodule 1Respiratory Aspiration 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1NSCLC 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Disease 1

Interventions

pembrolizumab 48Carboplatin 34Pemetrexed 28Cisplatin 25Docetaxel 23Nivolumab 21Paclitaxel 20Gemcitabine 15Magnetic Resonance Spectroscopy 14Specimen Handling 12Radiotherapy 12Cyclophosphamide 12Radiosurgery 11130-nm albumin-bound paclitaxel 11Erlotinib Hydrochloride 10Bevacizumab 10osimertinib 9Cetuximab 8Temozolomide 7Taxes 7Ipilimumab 7Biopsy 7fludarabine 6Ramucirumab 6Radiation 6veliparib 5tislelizumab 5durvalumab 5cemiplimab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Anterior Temporal Lobectomy × Thoracic × Clear all
NCT04931420 2024-07-31

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

University of Chicago

Phase 2 Withdrawn
GastrointestinalThoracic

Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡